Abeona Therapeutics (ABEO): JAMA Offers Detail On EB-101 Phase I Results - FBR
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Abeona Therapeutics (NASDAQ: ABEO) after closely reviewing results from the Phase I clinical trial with EB-101, recently published in the Journal of the American Medical Association (JAMA) and came away with a positive view of prospects for a safe, potentially durable, cell-based therapy for people with recessive dystrophic epidermolysis bullosa (RDEB).
The analyst thinks clinical efficacy demonstrated by EB-101 in 67% of healed wounds at six months, post-treatment (which lasted through 12 months), is impressive. He also thinks the restoration of Type VII collagen (C7) expression (lacking or poorly functional in RDEB) was also remarkable, especially at the graft site dermal-epidermal junction, where nutrient exchange and skin renewal occurs.
The analyst thinks news flow from EB-101 and Abeona's three other ongoing rare disease clinical programs in the next three to six months to be a positive catalyst for ABEO shares. We reiterate Outperform.
No change to the price target of $15.
Shares of Abeona Therapeutics closed at $6.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) PT Raised to $96 at UBS Following 2Q Report
- Barclays Downgrades Performance Food Group (PFGC) to Equalweight
- UPDATE: Seaport Global Securities Upgrades Columbus McKinnon (CMCO) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!